Growth Hormone Deficiency – Epidemiology – Mature Markets

DRG Epidemiology's coverage of growth hormone deficiency (GHD) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of GHD for each country as well as annualized case counts projected to the national population.

DRG Epidemiology's GHD forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of GHD over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Note: Coverage may vary by country.

Table of contents

  • Growth Hormone Deficiency - Epidemiology - Mature Markets
    • Introduction
      • Key Findings
      • Key Updates
      • Diagnosed Incidence of Growth Hormone Deficiency per Year per 100,000 People of All Ages in 2021 and 2041ttttttttt
      • Relative Sizes of the Factors Contributing to the Trend in Diagnosed Incident Cases of Growth Hormone Deficiency Over the Next 20 Years
    • Epidemiology Data
    • Methods
      • Diagnosed Incident Cases
      • Diagnosed Lifetime Prevalent Cases
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Growth Hormone Deficiency
        • Studies Excluded from the Analysis of Growth Hormone Deficiency
      • Risk/Protective Factors
        • Risk/Protective Factors for Growth Hormone Deficiency
      • Bibliography
      • Abbreviation Table
      • Glossary